Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Medicinal Chemistry

• Publication date

  2015-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/0929867322666150227153308PMID 25723507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Saxagliptin: a novel antiparkinsonian approach.

  2015cited by this paper
• Brain metabolic dysfunction at the core of Alzheimer's disease.

  2014cited by this paper
• Association of diabetes with amnestic and nonamnestic mild cognitive impairment

  2014cited by this paper
• Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.

  2014cited by this paper
• Substance P Exacerbates Dopaminergic Neurodegeneration through Neurokinin-1 Receptor-Independent Activation of Microglial NADPH Oxidase

  2014cited by this paper
• Current pathophysiological concepts in cerebral small vessel disease

  2014cited by this paper
• Gastrin‐Releasing Peptide Contributes to the Regulation of Adult Hippocampal Neurogenesis and Neuronal Development

  2014cited by this paper
• Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.

  2014cited by this paper
• Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study.

  2014cited by this paper
• In vitro aggregation assays for the characterization of α-synuclein prion-like properties

  2014cited by this paper
• Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases

  2014cited by this paper
• GLP-1R activation for the treatment of stroke: Updating and future perspectives

  2014cited by this paper
• Severe Hypoglycemia and Cognitive Decline in Older People With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study

  2014cited by this paper
• Severe Diabetic Retinal Disease and Dementia Risk in Type 2 Diabetes

  2014cited by this paper
• Impaired glycemia increases disease progression in mild cognitive impairment.

  2014cited by this paper
• Deregulation of brain insulin signaling in Alzheimer’s disease

  2014cited by this paper
• Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease

  2014cited by this paper
• Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease

  2014cited by this paper
• Interventions that Improve Body and Brain Bioenergetics for Parkinson's Disease Risk Reduction and Therapy

  2014cited by this paper
• Insulin Regulates Brain Function, but How Does It Get There?

  2014cited by this paper
• Transport and diffusion of Tau protein in neurons

  2014cited by this paper
• System-based approaches to decode the molecular links in Parkinson's disease and diabetes.

  2014cited by this paper
• Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects.

  2014cited by this paper
• Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

  2014cited by this paper
• The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.

  2014cited by this paper
• The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

  2014cited by this paper
• Brain imaging in type 2 diabetes.

  2014cited by this paper
• P2–389: Saxagliptin: A dipeptidyl peptidase‐4 inhibitor ameliorates streptozotocin‐induced Alzheimer's disease

  2013cited by this paper
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

  2013cited by this paper
• Glucose levels and risk of dementia.

  2013cited by this paper
• Systemic Administration of Substance P Recovers Beta Amyloid-Induced Cognitive Deficits in Rat: Involvement of Kv Potassium Channels

  2013cited by this paper
• Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.

  2013cited by this paper
• Vildagliptin: an anti‐diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin‐induced Alzheimer's disease

  2013cited by this paper
• Dementia in the oldest old: a multi-factorial and growing public health issue

  2013cited by this paper
• Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure

  2013cited by this paper
• MEROPS: the database of proteolytic enzymes, their substrates and inhibitors

  2013cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• Prognostic implications of DPP‐4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting – results of the 1 year follow‐up of the prospective DiaRegis registry

  2013cited by this paper
• Cardiovascular Disease and Cognitive Decline in Postmenopausal Women: Results From the Women's Health Initiative Memory Study

  2013cited by this paper
• DPP4‐inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high‐fat diet consumption

  2013cited by this paper
• Cyclic AMP promotes axon regeneration, lesion repair and neuronal survival in lampreys after spinal cord injury.

  2013cited by this paper
• DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?

  2013cited by this paper
• Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

  2013cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

  2013cited by this paper
• DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.

  2013cited by this paper
• Interaction of dipeptydil peptidase IV with amyloid peptides.

  2013cited by this paper
• Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.

  2012cited by this paper
• Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing‐induced heart failure

  2012cited by this paper
• α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells.

  2012cited by this paper
• Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

  2012cited by this paper
• Integration of cellular bioenergetics with mitochondrial quality control and autophagy

  2012cited by this paper
• Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats

  2012cited by this paper
• Newly diagnosed type 2 diabetes and risk of dementia: a population-based 7-year follow-up study in Taiwan.

  2012cited by this paper
• Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

  2012cited by this paper
• Risk of Alzheimer’s Disease in Relation to Diabetes: A Population-Based Cohort Study

  2012cited by this paper
• Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.

  2012cited by this paper
• DPP-4 inhibitors in the treatment of type 2 diabetes.

  2012cited by this paper
• Diabetes as a risk factor for dementia and mild cognitive impairment: a meta‐analysis of longitudinal studies

  2012cited by this paper
• Enhanced Expression of Glia Maturation Factor Correlates with Glial Activation in the Brain of Triple Transgenic Alzheimer’s Disease Mice

  2012cited by this paper
• Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective.

  2012cited by this paper
• DPP-4 Inhibitors

  2011cited by this paper
• Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

  2011cited by this paper
• Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

  2011cited by this paper
• Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Glucose tolerance status and risk of dementia in the community

  2011cited by this paper
• Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

  2011cited by this paper
• DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

  2011cited by this paper
• Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.

  2011cited by this paper
• Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety.

  2011cited by this paper
• Diabetes and Risk of Parkinson’s Disease

  2011cited by this paper
• Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

  2011cited by this paper
• Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders.

  2010cited by this paper
• Diabetes, Alzheimer disease, and vascular dementia

  2010cited by this paper
• Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

  2010cited by this paper
• Peptidomics of the Prolyl Peptidases

  2010cited by this paper
• Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

  2010cited by this paper
• Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.

  2009cited by this paper
• Benzimidazolium Salts as Small, Nonpeptidic and BBB‐Permeable Human Prolyl Oligopeptidase Inhibitors

  2008cited by this paper
• Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronal and astrocyte cultures and cerebral cortical slices.

  2007cited by this paper
• AD lesions and infarcts in demented and non‐demented Japanese‐American men

  2005cited by this paper
• Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

  2005cited by this paper
• Silent brain infarcts and the risk of dementia and cognitive decline.

  2003cited by this paper
• Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population.

  1996cited by this paper
• Vascular dementia

  1993cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Metformin vs. second-line therapy for delirium prevention in type 2 diabetes: A multinational study.

  2025cites this paper
• Pilot-Scale Production of Sericin-Derived Oligopeptides (SDOs) from Yellow Silk Cocoons: Peptide Characterization and Specifications

  2025cites this paper
• A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease.

  2024cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• "NO" controversy? : a controversial role in insulin signaling of diabetic encephalopathy.

  2024cites this paper
• Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by Vildagliptin.

  2022cites this paper
• Plasma sDPP4 (Soluble Dipeptidyl Peptidase-4) and Cognitive Impairment After Noncardioembolic Acute Ischemic Stroke

  2022cites this paper
• Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients

  2021cites this paper
• VALIDATION OF DIABETES ASSOCIATED DEPRESSION BY STREPTOZOTOCIN INDUCED RAT MODEL

  2021cites this paper
• Linagliptin, the dipeptidyl peptidase‐4 enzyme inhibitor, lessens CHOP and GRP78 biomarkers levels in cisplatin‐induced neurobehavioral deficits: A possible restorative gateway

  2020cites this paper
• mTOR-Autophagy: A Key for Geniposide Protection in APP/PS1 Transgenic Mice

  2020cites this paper
• Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications

  2020cites this paper
• Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease

  2019cites this paper
• Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

  2019cites this paper
• Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review

  2019cites this paper
• Sitagliptin promotes mitochondrial biogenesis in human SH‐SY5Y cells by increasing the expression of PGC‐1α/NRF1/TFAM

  2019cites this paper
• The Relevance of Insulin Action in the Dopaminergic System

  2019cites this paper
• Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase‐4 inhibitor

  2018cites this paper
• Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus.

  2018cites this paper
• Tackling dipeptidyl peptidase IV in neurological disorders

  2018cites this paper
• Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss

  2018cites this paper
• Dipeptidyl peptidase IV, which probably plays important roles in Alzheimer disease (AD) pathology, is upregulated in AD brain neurons and associates with amyloid plaques.

  2018cites this paper
• Pathophysiological Roles of Brain Aquaporins in Parkinson’s Disease and Aging

  2018cites this paper
• Alogliptin, DPP4 Inhibitor, Improved Cognitive and Depressive Function in Obese ApoE-/- Mice with Modification of BDNF in Hippocampus

  2017cites this paper
• Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment.

  2017cites this paper
• Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: historical overview and future prospects

  2017cites this paper
• The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer’s Disease, Based on a Mechanistic Target of Rapamycin Pathway

  2017cites this paper
• Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease

  2017cites this paper
• Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.

  2017cites this paper
• Insulin resistance and Parkinson's disease: A new target for disease modification?

  2016cites this paper
• Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

  2016influential citation
• Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.

  2016cites this paper
• Parkinson's Disease, Diabetes and Cognitive Impairment.

  2016influential citation
• Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease

  2016cites this paper
• Reduced incidence of Parkinson's disease after dipeptidyl peptidase‐4 inhibitors—A nationwide case‐control study

  2016cites this paper
• Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia

  2016cites this paper
• Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders.

  2016cites this paper